DNA X, Inc.
DNA X, Inc. Fundamental Analysis
DNA X, Inc. (SONM) shows moderate financial fundamentals with a PE ratio of -1.07, profit margin of -56.48%, and ROE of 15.15%. The company generates $0.0B in annual revenue with weak year-over-year growth of -37.74%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 27.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SONM's fundamental strength across five key dimensions:
Efficiency Score
WeakSONM struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSONM trades at attractive valuation levels.
Growth Score
WeakSONM faces weak or negative growth trends.
Financial Health Score
ModerateSONM shows balanced financial health with some risks.
Profitability Score
WeakSONM struggles to sustain strong margins.
Key Financial Metrics
Is SONM Expensive or Cheap?
P/E Ratio
SONM trades at -1.07 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SONM's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values DNA X, Inc. at -51.00 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.03 times EBITDA. This is generally considered low.
How Well Does SONM Make Money?
Net Profit Margin
For every $100 in sales, DNA X, Inc. keeps $-56.48 as profit after all expenses.
Operating Margin
Core operations generate -54.43 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.15 in profit for every $100 of shareholder equity.
ROA
DNA X, Inc. generates $-83.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
DNA X, Inc. generates limited operating cash flow of $-2.72M, signaling weaker underlying cash strength.
Free Cash Flow
DNA X, Inc. generates weak or negative free cash flow of $-2.72M, restricting financial flexibility.
FCF Per Share
Each share generates $-2.64 in free cash annually.
FCF Yield
SONM converts -6.97% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-1.07
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
-51.00
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.06
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-7.23
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.78
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
15.15
vs 25 benchmark
ROA
Return on assets percentage
-0.83
vs 25 benchmark
ROCE
Return on capital employed
-23.60
vs 25 benchmark
How SONM Stacks Against Its Sector Peers
| Metric | SONM Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -1.07 | 33.94 | Better (Cheaper) |
| ROE | 1515.04% | 1002.00% | Excellent |
| Net Margin | -56.48% | -48794.00% (disorted) | Weak |
| Debt/Equity | -7.23 | 0.44 | Strong (Low Leverage) |
| Current Ratio | 0.78 | 5.74 | Weak Liquidity |
| ROA | -83.01% | -288341.00% (disorted) | Weak |
SONM outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews DNA X, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-80.23%
Industry Style: Growth, Innovation, High Beta
DecliningEPS CAGR
48.64%
Industry Style: Growth, Innovation, High Beta
High GrowthFCF CAGR
90.02%
Industry Style: Growth, Innovation, High Beta
High Growth